WO1999041383A8 - Antigen library immunization - Google Patents

Antigen library immunization

Info

Publication number
WO1999041383A8
WO1999041383A8 PCT/US1999/002944 US9902944W WO9941383A8 WO 1999041383 A8 WO1999041383 A8 WO 1999041383A8 US 9902944 W US9902944 W US 9902944W WO 9941383 A8 WO9941383 A8 WO 9941383A8
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
antigen library
library immunization
obtaining
methods
Prior art date
Application number
PCT/US1999/002944
Other languages
French (fr)
Other versions
WO1999041383A1 (en
Inventor
Juha Punnonen
Steven H Bass
Robert Gerald Whalen
Russell Howard
Willem P C Stemmer
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to AU32891/99A priority Critical patent/AU3289199A/en
Priority to EP19990932510 priority patent/EP1054973A1/en
Priority to CA 2320958 priority patent/CA2320958A1/en
Priority to JP2000531564A priority patent/JP2002507393A/en
Publication of WO1999041383A1 publication Critical patent/WO1999041383A1/en
Publication of WO1999041383A8 publication Critical patent/WO1999041383A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
PCT/US1999/002944 1998-02-11 1999-02-10 Antigen library immunization WO1999041383A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU32891/99A AU3289199A (en) 1998-02-11 1999-02-10 Antigen library immunization
EP19990932510 EP1054973A1 (en) 1998-02-11 1999-02-10 Antigen library immunization
CA 2320958 CA2320958A1 (en) 1998-02-11 1999-02-10 Antigen library immunization
JP2000531564A JP2002507393A (en) 1998-02-11 1999-02-10 Antigen library immunization

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2176998A 1998-02-11 1998-02-11
US7429498P 1998-02-11 1998-02-11
US60/074,294 1998-02-11
US09/021,769 1998-02-11
US10550998P 1998-10-23 1998-10-23
US60/105,509 1998-10-23

Publications (2)

Publication Number Publication Date
WO1999041383A1 WO1999041383A1 (en) 1999-08-19
WO1999041383A8 true WO1999041383A8 (en) 1999-09-30

Family

ID=27361726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/002944 WO1999041383A1 (en) 1998-02-11 1999-02-10 Antigen library immunization

Country Status (5)

Country Link
EP (1) EP1054973A1 (en)
JP (1) JP2002507393A (en)
AU (1) AU3289199A (en)
CA (1) CA2320958A1 (en)
WO (1) WO1999041383A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8965101B2 (en) 2007-05-31 2015-02-24 Monsanto Technology Llc Seed sorter
US8959833B2 (en) 2004-08-26 2015-02-24 Monsanto Technology Llc Methods of seed breeding using high throughput nondestructive seed sampling
US8997398B2 (en) 2006-03-02 2015-04-07 Monsanto Technology Llc Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds
US9383291B2 (en) 2006-03-02 2016-07-05 Monsanto Technology Llc Automated contamination-free seed sampler and methods of sampling, testing and bulking seeds
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
WO1999023107A1 (en) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
KR20010052894A (en) 1998-06-17 2001-06-25 맥시겐, 인크. Method for producing polynucleotides with desired properties
US6605430B1 (en) 1998-08-12 2003-08-12 Maxygen, Inc. DNA shuffling of monooxygenase genes for production of industrial chemicals
JP2002526107A (en) 1998-10-07 2002-08-20 マキシジェン， インコーポレイテッド DNA shuffling to generate nucleic acids for mycotoxin detoxification
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
AUPP706098A0 (en) * 1998-11-11 1998-12-03 North Western Health Care Network Biological compositions, components thereof and uses therefor
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
EP1108783A3 (en) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonucleotide-mediated nucleic acid recombination
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
EP1214407A2 (en) * 1999-09-21 2002-06-19 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for identifying mhc-restricted antigens
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
GB9928787D0 (en) * 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2105601A (en) * 1999-12-17 2001-06-25 Maxygen, Inc. Methods for parallel detection of compositions having desired characteristics bymeans of mri spectroscopy
WO2001059071A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
AU2004260931B9 (en) 2003-04-29 2012-01-19 E.I. Du Pont De Nemours And Company Novel glyphosate-N-acetyltransferase (GAT) genes
US7367155B2 (en) 2000-12-20 2008-05-06 Monsanto Technology Llc Apparatus and methods for analyzing and improving agricultural products
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
EP2301553A1 (en) * 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
CA2481479C (en) 2002-02-26 2012-12-11 Maxygen, Inc. Novel flavivirus antigens
ES2564570T3 (en) 2002-03-01 2016-03-23 Codexis Mayflower Holdings, Llc Methods, systems and software for the identification of functional biomolecules
JP4851687B2 (en) 2002-03-09 2012-01-11 マキシジェン， インコーポレイテッド Crossover optimization for directed evolution
BR0309017B1 (en) 2002-04-04 2015-02-18 Monsanto Technology Llc AUTOMATIC MACHINE FOR HANDLING AND HANDLING INDIVIDUAL PARTS OF PRIVATE MATERIAL
AU2003228474A1 (en) * 2002-04-09 2003-10-27 Rmf Dictagene S.A. Secretory signal sequences and uses thereof
EP2298871A1 (en) 2002-04-19 2011-03-23 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2494798A1 (en) 2002-08-06 2005-01-13 Verdia, Inc. Ap1 amine oxidase variants
EP3023498B1 (en) 2003-03-06 2018-11-28 BASF Enzymes LLC Amylases, nucleic acids encoding them and methods for making and using them
EP3299465A1 (en) 2003-03-07 2018-03-28 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP1613733B1 (en) 2003-04-04 2015-06-03 BASF Enzymes LLC Pectate lyases, nucleic acids encoding them and methods for making and using them
JP2007529993A (en) 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー Glucanases, nucleic acids encoding them and methods for making and using them
WO2005021714A2 (en) 2003-08-11 2005-03-10 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
WO2005031367A2 (en) 2003-09-23 2005-04-07 Monsanto Technology Llc High throughput automated seed analysis system
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
CA2734624A1 (en) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Plastid transit peptides
EP2468853B1 (en) 2004-06-16 2015-04-01 DSM IP Assets B.V. Method for enzymatic decolorization of pheophytin
MX2007002307A (en) 2004-08-26 2007-04-16 Monsanto Technology Llc Automated testing of seeds.
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
EP1861506B1 (en) 2005-03-15 2015-04-15 BP Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
EP1888622A1 (en) * 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
NZ595501A (en) 2006-02-10 2013-05-31 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
US8043839B2 (en) 2006-02-14 2011-10-25 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
CA2644548A1 (en) * 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
AU2007223888A1 (en) * 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
CN101437954B (en) 2006-03-07 2015-09-09 嘉吉公司 The nucleic acid of zymohexase and coding zymohexase and their preparation and application
CN101443446B (en) 2006-03-07 2013-08-21 维莱尼姆公司 Aldolases, nucleic acids encoding them and methods for making and using them
CA2656676C (en) 2006-06-28 2016-04-26 Monsanto Technology Llc Small object sorting system and method
MX369001B (en) 2006-08-04 2019-10-24 Basf Enzymes Llc Glucanases, nucleic acids encoding them and methods for making and using them.
PT2397486E (en) 2006-09-21 2015-03-23 Basf Enzymes Llc Phytases, nucleic acids encoding them and methods for making and using them
MX2009003034A (en) 2006-09-21 2009-11-18 Verenium Corp Phospholipases, nucleic acids encoding them and methods for making and using them.
ES2620288T3 (en) 2006-12-21 2017-06-28 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids that encode them and methods to form and use them
BRPI0807132A2 (en) 2007-01-30 2018-12-04 Syngenta Participations Ag enzymes for the treatment of lignocellulosics, nucleic acids encoding them, and methods and use thereof
EP2000531A1 (en) * 2007-06-06 2008-12-10 Biomay AG Antigen presenting cells
KR20100058541A (en) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 Compositions and methods for modifying properties of biologically active polypeptides
EP2205744B1 (en) 2007-10-03 2015-01-14 BP Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
JP5563990B2 (en) 2008-01-03 2014-07-30 ヴェレニウム コーポレイション Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
US8541220B2 (en) 2008-01-03 2013-09-24 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
EP3115459A3 (en) 2008-05-23 2017-04-26 E. I. du Pont de Nemours and Company Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
NZ592070A (en) 2008-09-26 2012-07-27 Tocagen Inc Gene therapy vectors and humanized yeast cytosine deaminase triple mutant
ES2730800T3 (en) 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Extended recombinant polypeptides and compositions comprising the same
CN106011159A (en) 2009-05-21 2016-10-12 巴斯夫酶有限责任公司 Phytases, nucleic acids encoding them and methods for making and using them
CA2770854A1 (en) 2009-08-20 2011-02-24 Pioneer Hi-Bred International, Inc. Functional expression of shuffled yeast nitrate transporter (ynt1) in maize to improve nitrate uptake under low nitrate environment
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
CA2786001A1 (en) 2009-12-31 2011-07-07 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
SI3564260T1 (en) 2012-02-15 2023-02-28 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
SG11201404711WA (en) 2012-02-16 2014-09-26 Vlp Therapeutics Llc Virus like particle composition
US20150184173A1 (en) 2012-05-04 2015-07-02 E I Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
US20160040149A1 (en) 2013-03-14 2016-02-11 Pioneer Hi-Bred International Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
US20140289906A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
AU2014244487A1 (en) * 2013-03-14 2015-10-15 Altravax, Inc. Hepatitis B virus vaccines
EP2971000A4 (en) 2013-03-15 2016-11-23 Pioneer Hi Bred Int Phi-4 polypeptides and methods for their use
TWI676636B (en) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US10006045B2 (en) 2013-08-16 2018-06-26 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3175967A1 (en) 2013-09-13 2015-03-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2015120270A1 (en) 2014-02-07 2015-08-13 Pioneer Hi Bred International, Inc. Insecticidal proteins and methods for their use
CA2939156A1 (en) 2014-02-07 2015-08-13 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
JP6824154B2 (en) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ Virus-like particles containing the modified envelope protein E3
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
CN113372421A (en) 2014-10-16 2021-09-10 先锋国际良种公司 Insecticidal proteins and methods of use thereof
CN107529763B (en) 2015-03-11 2021-08-20 先锋国际良种公司 Insecticidal combinations of PIP-72 and methods of use
FI3760737T3 (en) * 2015-05-11 2023-07-17 Illumina Inc Platform for discovery and analysis of therapeutic agents
CN116333064A (en) 2015-05-19 2023-06-27 先锋国际良种公司 Insecticidal proteins and methods of use thereof
WO2017024084A1 (en) 2015-08-03 2017-02-09 University Of Washington Immunogenic compositions, antigen screening methods, and methods of generating immune responses
CN108472337B (en) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 Factor IX fusion proteins and methods of making and using same
US11198709B2 (en) 2015-08-06 2021-12-14 E. I. Du Pont De Nemours And Company Plant derived insecticidal proteins and methods for their use
EP3390431A1 (en) 2015-12-18 2018-10-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX2018013249A (en) 2016-05-04 2019-02-13 Pioneer Hi Bred Int Insecticidal proteins and methods for their use.
US11155829B2 (en) 2016-07-01 2021-10-26 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
US11021716B2 (en) 2016-11-01 2021-06-01 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3044404A1 (en) 2016-12-14 2018-06-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2018118811A1 (en) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
US20190390219A1 (en) 2017-02-08 2019-12-26 Pioneer Hi-Bred International, Inc. Insecticidal combinations of plant derived insecticidal proteins and methods for their use
CN110621780B (en) 2017-05-11 2024-03-19 先锋国际良种公司 Insecticidal proteins and methods of use thereof
US20230235352A1 (en) 2020-07-14 2023-07-27 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8959833B2 (en) 2004-08-26 2015-02-24 Monsanto Technology Llc Methods of seed breeding using high throughput nondestructive seed sampling
US8997398B2 (en) 2006-03-02 2015-04-07 Monsanto Technology Llc Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds
US9383291B2 (en) 2006-03-02 2016-07-05 Monsanto Technology Llc Automated contamination-free seed sampler and methods of sampling, testing and bulking seeds
US9551636B2 (en) 2006-03-02 2017-01-24 Monsanto Technology Llc Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds
US8965101B2 (en) 2007-05-31 2015-02-24 Monsanto Technology Llc Seed sorter
US9275265B2 (en) 2007-05-31 2016-03-01 Monsanto Technology Llc Seed sorter
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Also Published As

Publication number Publication date
JP2002507393A (en) 2002-03-12
CA2320958A1 (en) 1999-08-19
EP1054973A1 (en) 2000-11-29
AU3289199A (en) 1999-08-30
WO1999041383A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
WO1999041383A8 (en) Antigen library immunization
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
CR8231A (en) ANTIBODIES RG1 AND USE OF THE SAME
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
GR3036229T3 (en) Method for the production of antihuman antigen receptors and uses thereof
WO2004001381A3 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO1999066879A3 (en) Systemic immune activation method using nucleic acid-lipid complexes
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2003030835A3 (en) Use of bispecific antibodies to regulate immune responses
HK1044159A1 (en) Humanized antibodies to gamma-interferon
WO2003054007A3 (en) Streptococcus antigens
MY125202A (en) Vaccine
IL139095A0 (en) Methods for amyloid removal using anti-amyloid antibodies
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2005120563A3 (en) Induction of an immune response against streptococcus pneumoniae polysaccharides
HUP9903770A2 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
AU4396401A (en) Composition and method for the prevention and/or the treatment of allergy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 33/99 UNDER (51) REPLACE THE EXISTING SYMBOLS BY "C12N 15/31, 15/36, 15/48, 15/51, C07K 19/00, 14/02, 14/16, 14/24, 14/035, 14/18, 14/31, 14/315, 14/28, 14/245, 14/35, 14/445, 14/435, C12N 15/10, 15/86"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2320958

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 531564

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2320958

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007892

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 32891/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999932510

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999932510

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999932510

Country of ref document: EP